Mutational Signature: COSMIC Signature SBS4

In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (transversion-high tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in transversion-low [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS.

Citations:

• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.